HK1252353A1 - 治疗精神分裂症的方法 - Google Patents

治疗精神分裂症的方法 Download PDF

Info

Publication number
HK1252353A1
HK1252353A1 HK18111638.5A HK18111638A HK1252353A1 HK 1252353 A1 HK1252353 A1 HK 1252353A1 HK 18111638 A HK18111638 A HK 18111638A HK 1252353 A1 HK1252353 A1 HK 1252353A1
Authority
HK
Hong Kong
Prior art keywords
compound
alkyl
group
ether
hydroxy
Prior art date
Application number
HK18111638.5A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of HK1252353A1 publication Critical patent/HK1252353A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18111638.5A 2011-08-05 2018-09-11 治疗精神分裂症的方法 HK1252353A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515418P 2011-08-05 2011-08-05
US61/515418 2011-08-05

Publications (1)

Publication Number Publication Date
HK1252353A1 true HK1252353A1 (zh) 2019-05-24

Family

ID=47627335

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111638.5A HK1252353A1 (zh) 2011-08-05 2018-09-11 治疗精神分裂症的方法

Country Status (18)

Country Link
US (2) US8592483B2 (enExample)
EP (1) EP2739278A4 (enExample)
JP (2) JP6193230B2 (enExample)
KR (1) KR20140076551A (enExample)
CN (2) CN107903173A (enExample)
AR (1) AR087468A1 (enExample)
AU (2) AU2012293157A1 (enExample)
BR (1) BR112014002712A8 (enExample)
CA (1) CA2842455A1 (enExample)
HK (1) HK1252353A1 (enExample)
IL (2) IL230552A (enExample)
MX (1) MX359697B (enExample)
NZ (1) NZ620300A (enExample)
RU (1) RU2648474C2 (enExample)
SG (1) SG10201606442QA (enExample)
TW (2) TWI619497B (enExample)
WO (1) WO2013022079A1 (enExample)
ZA (1) ZA201400707B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450128B (zh) * 2013-08-15 2015-04-08 河南中帅医药科技股份有限公司 用于治疗青光眼的前列腺素类似物中间体Corey醛的制备方法
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
US7211703B2 (en) * 2005-04-27 2007-05-01 Calgon Carbon Corporation Method of separating E and Z isomers of an alkene alcohol and derivatives thereof
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
EP2178516B1 (en) * 2007-07-19 2015-09-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
TWI619498B (zh) 2018-04-01
MX359697B (es) 2018-10-08
US8592483B2 (en) 2013-11-26
CN103841966A (zh) 2014-06-04
TW201808302A (zh) 2018-03-16
EP2739278A1 (en) 2014-06-11
US20140031428A1 (en) 2014-01-30
BR112014002712A2 (pt) 2017-06-13
US20130035393A1 (en) 2013-02-07
RU2648474C2 (ru) 2018-03-26
NZ620300A (en) 2015-09-25
CA2842455A1 (en) 2013-02-14
EP2739278A4 (en) 2015-03-18
BR112014002712A8 (pt) 2017-06-20
AU2017203092A1 (en) 2017-06-01
AU2012293157A1 (en) 2014-03-13
MX2014001409A (es) 2014-05-28
AU2017203092B2 (en) 2018-11-08
CN107903173A (zh) 2018-04-13
IL230552A0 (en) 2014-03-31
WO2013022079A1 (en) 2013-02-14
JP2014527048A (ja) 2014-10-09
TW201316992A (zh) 2013-05-01
TWI619497B (zh) 2018-04-01
RU2014108423A (ru) 2015-09-10
IL230552A (en) 2017-09-28
JP2017222708A (ja) 2017-12-21
IL254289A0 (en) 2017-10-31
ZA201400707B (en) 2014-11-26
JP6193230B2 (ja) 2017-09-06
KR20140076551A (ko) 2014-06-20
SG10201606442QA (en) 2016-09-29
AR087468A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
EP0435443B1 (en) Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5252605A (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
CA2445651C (en) Cathartic composition comprising halogenated prostaglandin derivatives
KR101354771B1 (ko) 중추 신경계 질환 치료를 위한 방법 및 조성물
HK1252353A1 (zh) 治疗精神分裂症的方法
CN1867310B (zh) 促进毛发生长的组合物及其用途
HK1196278A (en) Method for treating schizophrenia
KR20120031954A (ko) 클라우딘 매개 기능을 조정하고 피부 장애를 치료하는데 사용하기 위한 프로스타글란딘 유도체를 포함하는 제약 조성물
JP2014515004A (ja) イオン輸送体の調節方法
EP2841065A1 (en) Method for treating irritable bowel syndrome with diarrhea